Biogen's first quarter results disappoint Wall Street

April 24, 2015 12:04 PM

50 0

Biogen's first quarter results disappoint Wall Street

Drugs company Biogen today posted lower then expected quarterly profit and revenue as its key oral multiple sclerosis drug Tecfidera showed signs of slowing growth.

The drug's sales have slowed after falling short of analysts' estimates for the first time in the third quarter of 2014.

Read more

To category page

Loading...